Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

scientific article published on 10 December 2018

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S2352-3026(18)30182-0
P932PMC publication ID6563344
P698PubMed publication ID30545576

P50authorNicholas J. ShortQ42365103
Rashmi Kanagal-shamannaQ43140093
Sanam LoghaviQ43242254
Jorge Eduardo CortesQ60320900
Hagop KantarjianQ60394812
Courtney D DiNardoQ60964369
Zeev EstrovQ64026337
Guillermo Garcia-ManeroQ66385413
Xuelin HuangQ87045391
Abhishek MaitiQ87632566
Elias J JabbourQ87641766
Naveen PemmarajuQ87733857
Prithviraj BoseQ88053364
Gautam BorthakurQ88200100
Naval DaverQ88327648
Tapan M KadiaQ88337925
Marina KonoplevaQ89564940
Steven M KornblauQ89882472
Maro OhanianQ90322123
Christopher B BentonQ90558065
Mary Ann RichieQ114427944
P2093author name stringWei Qiao
Nitin Jain
Farhad Ravandi
Sherry Pierce
Yesid Alvarado
Yvonne Gasior
P2860cites workPrognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidineQ27853006
Acute Myeloid LeukemiaQ28267442
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemiaQ33401766
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous LeukemiaQ33702409
Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic featuresQ33782633
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineQ33841988
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsQ34398397
Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsQ35126237
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.Q35486110
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsQ35859212
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.Q35921904
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid LeukemiaQ36208652
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemiaQ36781942
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agentsQ37046564
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemiaQ37462852
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesQ37566878
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoringQ37618897
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemiaQ37635209
Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndromeQ37688233
Acute myeloid leukemia and myelodysplastic syndromes in older adultsQ38234863
Selecting initial treatment of acute myeloid leukaemia in older adultsQ38981876
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomesQ39555179
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaQ40543180
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignanciesQ44646952
Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysisQ46117117
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimensQ46317683
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyQ47655563
Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups.Q50859525
Molecular Minimal Residual Disease in Acute Myeloid LeukemiaQ57201597
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcomeQ82366072
Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapyQ86562578
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortQ88446399
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid LeukemiaQ88493206
P433issue1
P921main subjectphase II clinical trialQ42824440
P304page(s)e29-e37
P577publication date2018-12-10
P1433published inThe Lancet. Haematology.Q26840042
P1476titleTreatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
P478volume6